Cargando…

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease

Secondary hyperparathyroidism (sHPT) represents the adaptive and very often, finally, maladaptive response of the organism to control the disturbed homeostasis of calcium, phosphorus, and vitamin D metabolism caused by declining renal function in chronic kidney disease (CKD). sHPT leads to cardiovas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friedl, Claudia, Zitt, Emanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436758/ https://www.ncbi.nlm.nih.gov/pubmed/28546765 http://dx.doi.org/10.2147/IJNRD.S97637

Ejemplares similares

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future
por: Brandenburg, Vincent, et al.
Publicado: (2022)

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease
por: Strugnell, Stephen A., et al.
Publicado: (2023)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease
por: Sonkar, Satyendra Kumar, et al.
Publicado: (2018)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD
por: Lu, Chien-Lin, et al.
Publicado: (2018)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2022)

Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
por: Chandran, Manju, et al.
Publicado: (2019)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Exacerbation of Hyperparathyroidism, Secondary to a Reduction in Kidney Function, in Individuals With Vitamin D Deficiency
por: Daimon, Makoto, et al.
Publicado: (2020)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D
por: Cozzolino, Mario, et al.
Publicado: (2021)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease
por: Lin, Li-Ping, et al.
Publicado: (2023)

A Python Analytical Pipeline to Identify Prohormone Precursors and Predict Prohormone Cleavage Sites
por: Southey, Bruce R., et al.
Publicado: (2008)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis
por: Cozzolino, Mario, et al.
Publicado: (2021)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital
por: Manjarres, Luis, et al.
Publicado: (2016)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Expression of mutant ELH prohormones in AtT-20 cells: the relationship between prohormone processing and sorting
Publicado: (1993)

Vitamin D and chronic kidney disease
por: Kim, Chang Seong, et al.
Publicado: (2014)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
por: Perrone, Valentina, et al.
Publicado: (2022)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Prohormones in the Early Diagnosis of Cardiac Syncope
por: Badertscher, Patrick, et al.
Publicado: (2017)

Vitamin D and osteoporosis in chronic kidney disease
por: Lips, Paul, et al.
Publicado: (2017)

Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19
por: Mazziotti, G., et al.
Publicado: (2021)

Vitamin D in Chronic Kidney Disease and Dialysis Patients
por: Jean, Guillaume, et al.
Publicado: (2017)

Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels
por: Zhao, Yu, et al.
Publicado: (2016)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ttco6tq2u1lrgaprd0dnh3c7jr